Open-house biologics rebate agreement for PEG-Epoetin beta
Titre original de l'avis
Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-38 - PEG-Epoetin beta
Score d'opportunité
Pourquoi ce score ?
Opportunité
52 / 100
Complexité
58 / 100
Facteurs de risque
For monthly inclusion in pharmacy software, complete documents must reach TK by the 3rd day of the previous month; late...
Portal submission is not allowed; contracts must be sent by email with qualified electronic signature or by post, which...
Analyse approfondie du portefeuille
Utilise:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Aperçu
Moderate opportunityFaits clés
- Supplies contract
- 1 lot
- Duration until Jan 2028
- Supply of pharmaceutical products for PEG-Epoetin beta under an open-house rebate agreement.
- Conclusion of rebate contracts with all suitable pharmaceutical manufacturers meeting the stated conditions.
Afficher le résumé complet
Open-house supply arrangement for PEG-Epoetin beta pharmaceutical products in Germany, led by Techniker Krankenkasse with HEK and hkk as participating buyers. The contract is non-exclusive, with no individual negotiations, and can be joined at any time during the contract period. The notice states a maximum duration of 24 months from 01.02.2026 to 31.01.2028. No contract value is provided. Submission is not via the portal; contracts must be sent by email with qualified electronic signature or by post, and the notice says the procurement documents are available online but were not fully analyzed as separate extracted document text is not provided beyond the XML notice.
Risques
For monthly inclusion in pharmacy software, complete documents must reach TK by the 3rd day of the previous month; late...
Portal submission is not allowed; contracts must be sent by email with qualified electronic signature or by post, which...
L'analyse peut être incomplète
Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.
Exigences clés
Technical
- Applicant must be a pharmaceutical undertaking within the meaning of § 4 Abs. 18 AMG for the relevant medicinal product.
- Applicant must have its seat in the AMG territory, another EU Member State, or another EEA state.
- Applicant must hold a valid marketing authorisation for the relevant medicinal product or otherwise be entitled to place it on the market in its own name.
Acheteur
Localisation
Hamburg, DEU
Site web
Identifiant
992-80116-93
Activité
Health
Lots (1)
LOT-0001
Open-house biologics rebate agreement for PEG-Epoetin beta
Open-house supply contract for rebate agreements under § 130c Abs. 1 SGB V for the active substance PEG-Epoetin beta. The lot is nationwide in Germany and is described as non-exclusive, with uniform conditions and no individual negotiations. The extracted XML notice indicates that contracts are opened directly and concluded once the stated conditions are met.
Localisation
Durée
Catégorie
Date limite
Détails des critères
Ziel ist der Abschluss von Arzneimittelrabattverträgen nach § 130c Abs. 1 SGB V zu dem Wirkstoff PEG-Epoetin beta im Rahmen eines Open-House-Verfahrens.
Note sur la valeur
Afficher les données TED originales
Titre original du lot
Open-House-Biologika-Rabattverträge 2025-38 - PEG-Epoetin beta
Description TED originale
Ziel ist der Abschluss von Arzneimittelrabattverträgen nach § 130c Abs. 1 SGB V zu dem Wirkstoff PEG-Epoetin beta im Rahmen eines Open-House-Verfahrens.
Détails de la procédure
- Date de publication
- 03 Dec 2025
- Langues
- German
Métadonnées de référence
- Base juridique
- 32014L0024
Identifiants de référence
- ID de l'appel d'offres
- 804419-2025
Documents (1)
Appels d'offres similaires
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Belgium – Pharmaceutical products – Antimycotica
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Score d'opportunité
Pourquoi ce score ?
Opportunité
52 / 100
Complexité
58 / 100
Facteurs de risque
For monthly inclusion in pharmacy software, complete documents must reach TK by the 3rd day of the previous month; late...
Portal submission is not allowed; contracts must be sent by email with qualified electronic signature or by post, which...
Analyse approfondie du portefeuille
Utilise:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications